Lambda Biologics

Startseite
Deutschland
Leipzig
Lambda Biologics

Lambda Biologics is a hub for bio-health knowledge and research, offering an advanced testing platform.

Explore animal-free solutions and experience fast and accurate results with the enhanced services of MyLab.

25/03/2026

Did you know tumors don’t act alone?
Cancer cells constantly communicate with their surroundings - immune cells, fibroblasts, and the extracellular matrix - forming what scientists call the tumor microenvironment (TME).

This dynamic ecosystem controls:
✅ Immune evasion
✅ Drug response
✅ Tumor progression

But here’s the challenge: Most traditional 2D monocultures isolate tumor cells, removing the very signals that define real tumor behavior. If we study cancer without its environment, we miss the full story.

To address this, Lambda Biologics provides an integrated TME co-culture system designed to better model tumor complexity and evaluate the response of modern oncology therapeutics - including Antibody-Drug Conjugates (ADCs), cell therapies, immunotherapies, and targeted small molecules.

Heading to AACR Annual Meeting 2026?
Visit us at Booth 1603 or book a meeting to discuss how your current models can better capture tumor–microenvironment interactions.

📌 April 17–22 San Diego Convention Center
📍 Booth 1603 | TME Interplay with Organoids
🔗 Book a meeting with us: https://calendar.app.google/Nk7hGn14LvV9nQBh8

23/03/2026

Congratulations to ORGANOIDSCIENCES on receiving IND approval from Korea’s MFDS for ATORM-C - an intestinal organoid-based regenerative therapy entering Phase 1 clinical trials for Crohn’s disease.

This milestone highlights the growing role of organoids in regenerative medicine - a field that Lambda Biologics is proud to help advance in partnership with ORGANOIDSCIENCES. In 2024, this platform secured a public funding from the Free State of Saxony, supported by the European Union, to accelerate the development of therapies within the Advanced Therapy Medicinal Products (ATMP) framework.

Through this collaboration, we are working to scale human-relevant organoid technologies and bring the next generation of regenerative medicine closer to patients.

A new therapeutic paradigm is emerging - and organoids are at its core.

📌 Read more: https://www.asiae.co.kr/en/article/bio-health/2026031615243829690

21/03/2026

On Brain Awareness Week, Lambda Biologics underscores the growing importance of advanced human-relevant in vitro systems in neuroscience research. 🧠

At Lambda Biologics, our specialized brain organoid research team develops physiologically relevant cerebral organoid models that recapitulate key features of human brain development and pathology. We collaborate with academic and industry partners to study neurodevelopmental and neurodegenerative disorders, including Alzheimer’s disease, autism spectrum disorder, microcephaly, and epilepsy.

These platforms enable mechanistic investigations, disease modeling, drug discovery, neurotoxicity assessment, and functional analysis of neuronal network activity in a controlled human context - helping bridge the gap between conventional models and clinical translation.

We welcome collaborative research opportunities to advance translational neuroscience and therapeutic innovation. Learn more: https://afs.lambda-bio.com/afs/cerebral-organoid/

16/03/2026

Visit Lambda Biologics Booth at AACR 2026!
📌 April 17–22 | San Diego Convention Center
📍 Booth 1603 | TME Interplay with Organoid

Learn more: https://afs.lambda-bio.com/blog/join-us-at-the-american-association-for-cancer-research-2026/

At AACR 2026, Lambda Biologics will demonstrate real-time immune–tumor interactions using our oncology-focused organoid platforms - built to capture the complexity that drives immunotherapy response and resistance.

Our integrated tumor organoid–TME platforms let you:
✅ Reconstruct patient-relevant tumor microenvironments in vitro
✅ Enable real-time observation of tumor growth and immune–tumor interactions
✅ Model ECM and stromal influences on tumor behavior
✅ Support mechanistic studies of cancer development
✅ Evaluate drug response and immune modulation in a physiologically relevant setting

🎁 AACR Exclusive Offer: Get 26% off Downstream Analysis for your oncology project.
👉 Book a meeting with us: https://calendar.app.google/Nk7hGn14LvV9nQBh8

14/03/2026

Working on colon cancer research? Lambda Biologics offers patient-derived Colorectal Cancer Organoids - 3D models that preserve the genetic mutations, cellular architecture, and tumor microenvironment complexity of real patient tumors.

What that means in practice:
✅ Pick organoid lines by specific driver mutation, thanks to our WES-characterized library
✅ Run drug sensitivity assays with clinically relevant compounds already benchmarked
✅ Explore immuno-oncology with TME co-culture models

More predictive. More relevant. More confidence in your results.

Curious how it fits your research? We'd love to hear what you're working on. 👇
https://afs.lambda-bio.com/afs/colorectal-cancer-organoid/

13/03/2026

Good cardiac models are hard to build.
Lambda Biologics built one worth talking about.

Our Cardiac Organoids are derived from human iPSCs through a matrix-free differentiation process - designed for consistency, built for relevance.

What the platform delivers:
→ A 3D model composed of cardiomyocytes, cardiac fibroblasts, and endothelial cells
→ Spontaneous contractility, validated by patch-clamp electrophysiology
→ Standardized process designed for batch-to-batch consistency
→ Available for customization by disease line or assay requirement

We believe the best preclinical tools earn trust through data, not claims.

Reach out if you'd like to explore how it fits your research.
https://afs.lambda-bio.com/afs/cardiac-organoid/

11/03/2026

Looking for a better way to evaluate immuno-oncology drugs?

Our cancer organoid co-culture system with and T cells enables more physiologically relevant drug testing by recreating key interactions within the tumor immune microenvironment.

By integrating macrophages with tumor organoids, the platform reveals distinct cytotoxic responses driven by the balance between M1 and M2 macrophages. Through controlled co-culture ratios of immune cells, we can model complex immune interactions and evaluate therapeutic responses more effectively.

The system enables simultaneous observation of:
✅ Macrophage phagocytic activity
✅ T cell-mediated cytotoxicity
✅ Immune responses influenced by M1/M2 macrophage dynamics

Using patient-derived tumor organoids together with macrophages and T cells, the model captures multi-immune cell mechanisms involved in tumor immunity. To support scalable testing, the system incorporates macrophages derived from pluripotent stem cells, enabling reproducible evaluation of drug candidates and antibodies.

📌Learn more: https://afs.lambda-bio.com/blog/cancer-organoid-co-culture-with-macrophages-and-t-cells-for-drug-evaluation/

06/03/2026

Some discoveries begin in a notebook. Others in a late night in the lab, or a quiet moment of refusing to give up. Behind so many of the breakthroughs transforming medicine, there is a woman - quietly powerful, always essential.

Today and every day, we see you, we honor you, and we are grateful. Happy International Women's Day. 🌸

05/03/2026

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers - and one major reason is its complex tumor microenvironment.

Beyond malignant epithelial cells, PDAC tumors are surrounded by dense stromal components, particularly cancer-associated fibroblasts (CAF) that actively reshape the extracellular matrix, influence signaling pathways, and affect how drugs pe*****te tumor tissue.

To better study these interactions, Lambda Biologics developed a 3D pancreatic cancer organoid co-culture platform with CAF, in collaboration with researchers at ORGANOIDSCIENCES & Seoul National University Hospital.

By integrating stromal components into patient-derived organoid systems, this model enables researchers to explore tumor–stroma interactions and microenvironment-driven mechanisms in a more biologically relevant setting.

📌 Read more: https://afs.lambda-bio.com/blog/pancreatic-cancer-organoid-co-culture-with-caf-for-tumor-microenvironment-modeling/

28/02/2026

For many rare disease patients, the journey to a diagnosis can take years. Treatment options are often limited - or nonexistent.
On Rare Disease Day, we recognize the urgency behind rare disease research.

When patient numbers are small, research models must be biologically accurate, scalable, and patient-relevant from the start.

Lambda Biologics works with patient-derived organoids to help researchers model rare disease mechanisms with higher translational confidence - accelerating discovery while honoring the value of every donated sample.
Because behind every “rare” disease is a very real patient waiting for answers.

26/02/2026

What if the most predictive drug testing model wasn’t an animal - but a miniature human organ? A recent article published in Nature explores how advanced human-based models are reshaping pathology research and drug development, accelerating the shift toward more human-relevant, animal-free approaches.

At , this is the future we’re working toward: building 3D human-relevant organoid platforms designed to enhance translational accuracy while reducing dependence on animal models.

📌 Learn more: https://afs.lambda-bio.com/blog/the-shift-beyond-animal-testing/
👀 Read the full article in Nature: https://www.nature.com/articles/d41586-026-00563-3
🤝 Explore our organoid services: https://afs.lambda-bio.com/organoid-service/

Image source: Nature 650, 812–814 (2026)
DOI: 10.1038/d41586-026-00563-3

Are you exploring animal-free alternatives in your research pipeline? We’d love to hear your perspective.

24/02/2026

Cholangiocarcinoma is one of oncology's hardest problems: Diagnosed late. Resistant to standard chemotherapy. For patients with advanced disease, median survival remains under 12 months. (Banales, J.M., Rodrigues, P.M., Affò, S. et al. Cholangiocarcinoma 2026: status quo, unmet needs and priorities. Nature Reviews Gastroenterology & Hepatology).

Better research models are urgently needed - and we believe organoids can play a meaningful role in changing that.

At Lambda Biologics, we've developed a Cholangiocarcinoma Organoid Service built for precision oncology research. Our models are:
✅ WES-characterized with key CCA driver mutations
✅ Validated for drug sensitivity testing across Gemcitabine, Cisplatin, Paclitaxel, and 5-FU
✅ Equipped with tumor microenvironment components for immuno-oncology applications

This work has been developed in collaboration with Seoul National University Hospital - and we're proud of how far it's come, while knowing there's still much more to do.

If you're researching CCA, we'd love to support your work.

🔗 Learn more: https://afs.lambda-bio.com/afs/cholangiocarcinoma-organoid/
💬 What challenges are you facing in your CCA research? We're always open to a conversation.

Adresse

Deutscher Platz. 5c
Leipzig
04103

Webseite

http://afs.lambda-bio.com/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Lambda Biologics erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.